Skip to search formSkip to main contentSkip to account menu

dalantercept

A soluble fusion protein containing the extracellular domain of activin receptor-like kinase-1 (ALK1) fused to a human Fc domain (ALK1-Fc fusion… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

ACE-041
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
This commentary reviews the novel mechanism of action of TRC105 in the context of treatments currently available for metastatic… 
2016
2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Purpose: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis. Concurrent targeting of ALK1 and VEGF signaling… 
Review
2016
Review
2016
Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
Angiogenesis is a hallmark of cancer and is now a validated therapeutic target in the clinical setting. Despite the initial… 
2016
2016
PHASE II evaluation of dalantercept for persistent or recurrent epithelial ovarian and related cancers: An NRG oncology study.
e17050Background: Activin receptor-like kinase 1 (ALK1) drives the maturation phase of angiogenesis. We conducted a two-stage… 
2015
2015
The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC).
4567 Background: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis involved in blood vessel maturation and… 
2015
2015
DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.
407 Background: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis involved in blood vessel maturation and… 
2014
2014
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.
5594 Background: Angiogenesis has a role in endometrial cancer (EC) progression and prognosis. Single agent bevacizumab had a… 
2014
2014
A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.
4566 Background: The activity of agents that target the vascular endothelial growth factor (VEGF) pathway in metastatic renal… 
2013
2013
Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
TPS6098 Background: Despite advances in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck… 
2012
2012
BMP9 as a potential biomarker for dalantercept efficacy against ALK1-mediated angiogensis in head and neck cancer.
30 Background: Activin receptor-like kinase 1 (ALK1) is a type 1 receptor in the TGF-β superfamily. The ALK1 pathway plays a role… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)